IGMS vs. ABUS, AVTE, YMAB, APLT, ALT, KALV, SIGA, CMPS, VERV, and ATXS
Should you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Arbutus Biopharma (ABUS), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Applied Therapeutics (APLT), Altimmune (ALT), KalVista Pharmaceuticals (KALV), SIGA Technologies (SIGA), COMPASS Pathways (CMPS), Verve Therapeutics (VERV), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Arbutus Biopharma (NASDAQ:ABUS) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
In the previous week, Arbutus Biopharma had 3 more articles in the media than IGM Biosciences. MarketBeat recorded 6 mentions for Arbutus Biopharma and 3 mentions for IGM Biosciences. Arbutus Biopharma's average media sentiment score of 0.63 beat IGM Biosciences' score of 0.32 indicating that IGM Biosciences is being referred to more favorably in the news media.
Arbutus Biopharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.
Arbutus Biopharma received 362 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 70.83% of users gave Arbutus Biopharma an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by insiders. Comparatively, 56.9% of IGM Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Arbutus Biopharma has higher revenue and earnings than IGM Biosciences. Arbutus Biopharma is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma has a net margin of -572.81% compared to Arbutus Biopharma's net margin of -11,255.25%. IGM Biosciences' return on equity of -62.68% beat Arbutus Biopharma's return on equity.
Arbutus Biopharma presently has a consensus price target of $4.33, indicating a potential upside of 45.41%. IGM Biosciences has a consensus price target of $17.89, indicating a potential upside of 94.02%. Given Arbutus Biopharma's higher probable upside, analysts clearly believe IGM Biosciences is more favorable than Arbutus Biopharma.
Summary
Arbutus Biopharma beats IGM Biosciences on 12 of the 18 factors compared between the two stocks.
Get IGM Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IGM Biosciences Competitors List
Related Companies and Tools
